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Abstract
The field of Alzheimer’s disease therapeutic research seems
poised to bring to clinic the next generation of treatments, moving
beyond symptomatic benefits to modification of the underlying
neurobiology of the disease. But a series of recent trials has had
disappointingly negative results that raise questions about our drug
development strategies. Consideration of ongoing programs
demonstrates difficult pitfalls. But a clear path forward is emerging.
Successful strategies will utilize newly available tools to reconsider
issues of diagnosis, assessment and analysis, facilitating the study
of new treatments at early stages in the disease process at which
they are most likely to yield major clinical benefits.
Alzheimer’s disease (AD) was described just over 100 years
ago as an uncommon devastating dementia affecting people
in middle age. In the 1970s, Dr Robert Katzman demon-
strated that AD is in fact an epidemic of enormous propor-
tions, affecting a substantial segment of the aging population
[1]. This spurred basic and clinical therapeutic research
activity, leading to the development of modestly effective
symptomatic treatments. While efforts to improve cognitive
and behavioral symptoms continue, the major focus of AD
therapeutic research is now disease modification - that is,
slowing the progression of the underlying neurobiology of AD
[2]. Alois Alzheimer described neuronal loss with formation of
plaques and tangles. Today’s leading programs target the
biochemical pathways leading to amyloid accumulation and
neurofibrillary tangle formation, and aim to protect neuronal
cells and synapses against dysfunction and destruction.
Clear targets have been identified. Two enzymes, beta
secretase and the gamma secretase complex, appear to be
essential for cleavage of the amyloidogenic Aβ fragment from
its transmembrane amyloid precursor protein (APP); inhibition
of one or both is expected to reduce amyloid accumulation
[3]. Genetic evidence provides strong support for these
approaches: all known genetic causes of AD either increase
the expression of APP or increase the generation of
amyloidogenic fragments. There is also hope that inhibiting
receptors that mediate Aβ trafficking [4,5] and toxicity [5,6]
may modify AD neurodegeneration. Tangle-related targets,
including kinase inhibitors aiming to reduce the hyper-
phosphorylation that characterizes the abnormal tau protein in
tangles [7], have seen more limited efforts. Neurotrophic
programs include direct neurosurgical delivery of nerve
growth factor to the nucleus basalis [8] using a viral vector.
But despite the proliferation of clinical development programs,
early results have been quite disappointing. The first two anti-
amyloid drugs to reach the pivotal stage of development,
tramiprosate and tarenflurbil, failed in phase III. What are the
implications of these failures? Are the targets wrong? Can
the field afford to invest the huge efforts and funds necessary
to continue to test potential disease-modifying treatments? Is
there any realistic likelihood of success?
Tramiprosate
Tramiprosate (also referred to as homotaurine and 3-amino-1-
propanesulfonic acid, or 3APS) is an Aβ-binding compound
that was developed using in vitro and in vivo model systems
[9] that left some uncertainty regarding the brain concen-
tration necessary for a pharmacodynamic effect in human AD.
While a phase II study did suggest a reduction in cerebro-
spinal fluid Aβ in AD subjects treated with tramiprosate [10],
it was unknown whether the degree of reduction would be
sufficient to translate into clinical benefit. The small and brief
phase II program was not designed to demonstrate clinically
a disease-slowing effect; as expected, subjects in the
12 week treatment trial treated with placebo showed no
decline, and, therefore, there was no possibility of showing
reduced decline with treatment. The development of
tramiprosate as a pharmaceutical treatment for AD was
halted when the first phase III trial failed to demonstrate
significant beneficial effects on the primary analysis of
cognitive and clinical outcomes.
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Tarenflurbil
Similar problems were faced in the tarenflurbil development
program.  In vitro and  in vivo, the drug clearly modulates
gamma secretase activity, reducing generation of Aβ [11,12].
In early human studies, however, there was no strong
biomarker evidence of amyloid reduction in cerebrospinal
fluid (CSF), and concerns about inadequate brain
concentrations in humans were voiced. The phase II trial,
though relatively large, was underpowered to show a
disease-modifying effect, and the primary analysis of the
impact of treatment on cognitive and functional outcomes
was negative [13]. However, post hoc analyses appeared to
be consistent with a beneficial drug effect, leading to the
launch of large phase III trials. The program was terminated
when the first phase III trial showed no evidence of beneficial
effect.
Bapineuzumab
A somewhat similar situation has arisen in the development
program of bapineuzumab, a monoclonal amino terminus-
specific anti-amyloid antibody [14]. Perhaps misled by
encouraging cognitive data from a small phase I trial hinting
at a symptomatic effect, the sponsors sought evidence of
efficacy in the modestly sized phase II program. Though there
was evidence of benefit in a number of secondary analyses,
particularly in the apolipoprotein E ε4 negative subgroup, the
primary cognitive efficacy analysis was negative. The
sponsors, Elan and Wyeth, have nonetheless proceeded with
a very large phase III program.
Why have so many programs yielded discouraging efficacy
data in phase II and III clinical trials? In phase II, the problem
may be primarily one of statistical power. Most programs seek
to be able to demonstrate a 25% to 33% slowing of
progression of mild or mild to moderate AD. But in view of
substantial inter-subject and inter-site variance issues, a large
and long trial is necessary. Estimates using preliminary data
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
[15] suggest that to demonstrate a 33% reduction in
progression rate (as measured by change in Alzheimer’s
Disease Assessment Scale-cognitive subscale (ADAS-cog)
or Clinical Dementia Rating ‘sum of boxes’ (CDR-SB)) in an
18 month trial in mild AD, approximately 300 subjects per
group are required (M Donohue et al., unpublished). No
phase II program has approached this size. It should be noted
that the ADNI experience probably underestimates the
sample size required, in that it may be expected that variance
will be greater in commercial trials, particularly those that are
international, than among the academic North American sites
participating in ADNI.
Other recent trials: Rember and dimebon
As with the anti-amyloid agents tramiprosate, tarenflurbil and
bapineuzumab, the phase II trial of the anti-tangle compound
Rember (methylene blue) did not meet its primary efficacy
objectives [16]. In view of the modest group sizes and short
duration, this too is not surprising, regardless of whether the
drug ultimately proves effective in pivotal trials. But as with
the anti-amyloid programs, caution must be exercised in the
interpretation of post hoc analyses of the Rember trial data.
The development of dimebon represents the one recent AD
program with strikingly positive results. At the primary 6
month analysis, strongly significant beneficial effects were
seen on all outcome measures [17]. With continuation of the
blind through 12 months of treatment, the effects on outcome
measures increased, consistent with (though not definitive
evidence of) a disease-modifying effect [17]. The success of
this modestly sized trial is indicative of the immediate
symptomatic benefit associated with the treatment. If a
putative disease modifying drug yields short-term benefits,
short (6 month) trials may be sufficient for regulatory approval.
Symptomatic effects are plausible with neuroprotective and
anti-amyloid drugs. But in the absence of such effects, a
modest, phase II-type trial will be insufficient; little or no
cognitive and clinical decline can be observed in 6 months,
so no slowing of progression can be demonstrated. A
consensus has arisen that 18 months or longer is an
appropriate duration of treatment for studies aiming to show
slowing of decline in AD.
But what about the two negative phase III trials of plausible
anti-amyloid agents? There was certainly a ‘phase II problem’ -
that is, phase III proceeded without evidence of efficacy in
phase II. As expected, the small phase II tramiprosate study
did not show any efficacy signal, but the modest reduction in
CSF Aβ42 was considered encouraging. But it is unknown
what the size of this biomarker signal must be to predict
clinical efficacy with prolonged treatment. Further, there were
questions about the magnitude and consistency of central
nervous system drug penetration and concentration. But in
addition to these uncertainties, the power of the phase III
North American tramiprosate trial was lower than expected.
The placebo group decline was smaller, and the standard
deviation of the change score was higher, than expected; the
power to demonstrate the target effect size of 25% slowing
with the group sizes of 350 was limited. The tarenflurbil
phase III program followed a phase II study that (not
surprisingly) failed to achieve its primary efficacy objectives,
so the risk of a negative phase III program had to be
considered substantial; only the post hoc phase II analyses
were encouraging. In addition, there was no convincing
evidence of pharmacodynamic effect; specifically, no
reduction in CSF Aβ in humans had been demonstrated. The
negative trial results may reflect inadequate brain penetration in
humans to yield a sufficient reduction in the generation of Aβ.
On the basis of these plausible explanations, the negative
results of the phase II and III anti-amyloid trials cannot be
considered to be strong evidence against the amyloid
cascade hypothesis. The scientific basis for the hypothesis
remains quite compelling. Aβ42 is highly toxic to neuronalcells and synaptic function, particularly in its oligomeric
states. Each of the known genetic causes of AD is closely
linked to Aβ generation: Down syndrome to APP over-
expression, and familial autosomal dominant AD to mutations
of APP and presinilins 1 and 2 that increase amyloidogenic
cleavage of APP. Occam’s Razor points strongly to amyloid
as the pivotal molecule. Recent reports of a small number of
AD patients with progressive dementia despite apparent
amyloid plaque clearance resulting from active vaccination
[18] does not disprove the hypothesis; clinical data on these
individuals are limited, plaques are probably not the most
important form of Aβ, the course of disease had these
patients not been treated is unknown, and perhaps earlier
treatment is necessary for a profound effect on outcome.
The need for early intervention
This last point may be key. There is strong evidence that the
pathiobiology of AD precedes dementia by many years. In
Down syndrome, amyloid deposition in brain precedes
dementia by years or decades [19,20]. There is a high
prevalence of brain amyloid in non-demented elderly
individuals at autopsy [21], perhaps an indication of a long
pre-symptomatic stage. Similarly, neuroimaging evidence of
brain amyloid deposition is common [22]. Subtle memory
symptoms and cognitive decline have been documented
more than a decade before dementia onset [23]. If, as
suggested by the recent active vaccine study autopsy report,
dementia can progress despite elimination of amyloid plaques
in AD patients [18], perhaps it is necessary to intervene
earlier in the disease process.
At present, the diagnosis of AD requires the presence of
dementia. What is the relationship of pre-dementia cognitive
dysfunction to AD? What is the significance of amyloid brain
deposition in the absence of cognitive impairment? With two
plausible (if not yet proven) methods for identifying brain
amyloid deposition, positron emission tomography (PET)
scanning and CSF measurement of Aβ42, identification of
such individuals is quite feasible. If either subtle cognitive
impairment or amyloid deposition in brain consistently
predicts AD dementia, it should be considered an early stage
of AD. That is, we should revise the standard NINCDS-
ADRDA criteria for AD [24].
Dubois and colleagues [25] have proposed one possible
revision. They suggest that a ‘research diagnosis’ of AD be
based on the presence of gradually progressive episodic
memory impairment with evidence of AD neurobiology docu-
mented by the presence of one or more among several
characteristic biomarker signals. The biomarker signals
include medial temporal lobe atrophy by volumetric magnetic
resonance imaging (MRI), temporal parietal hypoperfusion by
[18F]fluorodeoxyglucose (FDG)-PET, amyloid deposition by
PET, or CSF findings (elevated tau or phospho-tau, and/or
low Aβ42) characteristic of AD. The proposed criteria can be
applied in the pre-dementia or dementia stages.
It is plausible that effective disease-modifying interventions
might be only minimally effective or even futile at the dementia
stage; neuroprotection or favorable effects on the inciting
amyloid dysregulation might be overwhelmed by extensive
neuronal/synaptic degeneration and plaque pathology. Extend-
ing the diagnosis of AD to include individuals with mild
cognitive impairment and even normal cognition when there is
biomarker evidence of AD-type pathophysiology might
facilitate the development of disease-modifying drugs for the
treatment of individuals most likely to respond. The earlier the
disease-modifying intervention, the greater the expected
impact on the disease course. This idea is supported by a
number of therapeutic studies in transgenic animal models
[26,27].
The design of early intervention trials
Altering the definition of AD may not be necessary for the
development of early interventions. A possible development
strategy for early intervention using the current diagnostic
criteria would be to conduct studies aiming to demonstrate
that an intervention increases the time to dementia diagnosis.
Several completed studies have enrolled subjects with
amnestic mild cognitive impairment (MCI), with the primary
analysis of survival to consensus diagnosis of AD [28]. This
design has the advantage of clear clinical validity, a desirable
feature in consideration of the uncertain regulatory status of
the MCI designation. At least one set of MCI criteria seems to
predict a high likelihood of AD diagnosis (approximately 15%
per year), so that such a trial can have a reasonable size with
adequate power to demonstrate a treatment effect [29]. But
progression from MCI to AD is not a discrete event; the loss
of function necessary to meet criteria for dementia occurs
gradually, and it is challenging to assign a specific date to
dementia onset. This subjectivity may be aggravated in large
international trials. The progression of cognitive and
functional impairment caused by AD pathobiology is
insidious; defining a discrete disease onset seems arbitrary.
If the diagnostic criteria for AD are modified to encompass
individuals prior to the onset of dementia, it would be straight-
forward to design trials with standard AD co-primary outcome
measures. The ADNI longitudinal data demonstrate accep-
table decline rate and variance for the ADAS-cog and CDR-
SB in amnestic MCI; the size of trials adequately powered to
demonstrate slowing of cognitive/clinical progression would
be large but perhaps manageable. Adding selection criteria,
and perhaps covariates to adjust for disease state, will
reduce sample sizes substantially. In particular, for the
development of anti-amyloid programs such as secretase
inhibitor, anti-aggregation agents and anti-amyloid immuno-
therapy, trials can select MCI patients with biomarker
evidence of brain amyloid deposition. Two options are
feasible, though each presents challenges. The advent of F18
amyloid binding radiotracers has established the feasibility of
amyloid brain imaging at most sites with PET scanners, but
this is an expensive undertaking that has not yet been fully
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ging evidence of amyloid deposition [30] and is essentially
universally available, though requiring lumbar puncture during
study screening may not be welcomed by investigators and
especially subjects. The addition of covariates such as MRI
volumetric measures to analysis plans will reduce unexplained
variance and further increase statistical power to demonstrate
slowing of progression. If the community of AD investigators,
clinicians and regulators were to adopt early AD diagnostic
criteria, feasible early AD trials could be launched
immediately (Table 1).
While disease-modifying treatment of MCI is expected to
yield more dramatic benefits than treatment of mild AD,
perhaps the most appropriate population for intervention is
the earlier, pre-symptomatic (or very mildly symptomatic)
subjects with biomarker evidence suggestive of AD. The
ultimate goal of disease-modification programs, prevention of
AD dementia, is conceivable if treatment is started before
appreciable neuronal damage and synaptic dysfunction have
occurred. Preliminary evidence from some studies suggest
that markers of amyloid accumulation predict dementia even
in asymptomatic individuals [31].
Validated surrogate markers in AD
But in the absence of symptoms, it will not be possible to
fulfill the conventional US Food and Drug Administration
requirement for AD drug development: demonstration of
efficacy on co-primary measures, specifically a cognitive
performance test and a functional/global measure. It would
require huge and lengthy studies to show slowing of
cognitive and clinical progression or delay to diagnosis of
dementia in subjects not yet showing any symptoms. To
study interventions in this population, we will require validated
surrogate markers.
A biomarker is any objectively measured characteristic that
reflects normal or pathological processes, or responses to
therapeutic intervention. As discussed above, biomarkers can
be valuable in selecting subjects for clinical trials and for
therapeutic interventions, for reducing unexplained variance
and thus improving statistical power, and for establishing
proof of concept in early phase drug development.
In rare cases, a biomarker can take the place of a clinical
endpoint for establishing efficacy in a phase III clinical trial;
that is, a biomarker can be validated as a surrogate endpoint.
Examples of such surrogate markers include blood glucose
and hgA1c in diabetes, blood pressure and cholesterol in
cardiovascular disease, intraocular pressure in glaucoma, and
lymphocyte subset ratios and viral load in HIV disease. To
validate a biomarker as a surrogate endpoint, several issues
must be addressed. There must be a well-accepted scientific
framework connecting the biomarker to disease mechanisms
and the prediction of clinical outcomes. Further, drug effects
on the biomarker must be related to drug effects on clinical
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Page 4 of 6
(page number not for citation purposes)
Table 1
Comparison of possible trial designs at different stages of Alzheimer’s disease neurobiology
Mild AD Trial Early AD Trial Very early AD Trial
Cognitive status Mild dementia Mild cognitive impairment Cognitively normal
CDR global score 0.5 to 1 0.5 0
MMSE range 16 to 26 25 to 30 28 to 30
Biomarker for subject selection None Amyloid imaging and/or CSF Aβ42 Amyloid imaging and/or CSF Aβ42
Biomarker for subject  None or APOE genotype APOE genotype APOE genotype
stratification
Primary cognitive outcome  ADAS-cog11 ADAS-cog12 (includes delayed  Sensitive memory and/or executive 
measure recall) function measure
Primary global/functional  CDR-SB CDR-SB None
outcome measure
Analysis covariates Baseline cognition and regional  Baseline cognition and regional  Regional brain volume
brain volume brain volume
Biomarker outcome  Regional brain atrophy Regional brain atrophy Regional brain atrophy and/or amyloid 
measure (as surrogate endpoint)
Duration of treatment 18 months 24 months 24 to 36 months
Primary analysis Change score or slope of  Change score or slope of  Regional brain atrophy rate and 
co-primaries: ADAS-cog11,  co-primaries: ADAS-cog12,  cognitive decline
CDR-SB CDR-SB
AD = Alzheimer’s disease; ADAS-cog = Alzheimer’s Disease Assessment Scale-cognitive subscale; APOE, apolipoprotein E; CDR-SB = Clinical
Dementia Rating ‘sum of boxes’; CSF = cerebrospinal fluid; MMSE, Mini-Mental State Examination.outcome; ideally, the biomarker should fully capture treatment
effects, as confirmed by clinical trials of multiple interventions.
It is unlikely that an ideal surrogate for disease-modifying
intervention in AD will become available in the foreseeable
future. However, in consideration of the enormous clinical
need, and the likelihood that the development of highly
effective disease-modifying treatments will require the use of
surrogate endpoints, it is reasonable to assume that
regulatory agencies will consider acceptance of surrogates
that are less than ideal.
A validated surrogate marker is essential for the study of AD
interventions in asymptomatic or very mildly symptomatic
individuals. It may be feasible to gain acceptance of a
surrogate AD biomarker with a small number of trials demon-
strating concordant treatment effects on the biomarkers and
clinical symptoms. Even if the benefits of disease-modifying
treatments in mild AD dementia are limited, they may well be
sufficient to establish this concordance. Indeed, ongoing anti-
amyloid trials that have incorporated biomarkers could
provide this evidence. Consensus among clinical experts,
based on robust data, that candidate biomarkers track
disease progression at various stages of disease will
strengthen the case for validation. A leading candidate
surrogate marker is brain atrophy rate as measured by
volumetric MRI; a huge body of evidence supports a link
between regional brain atrophy and progression of AD
pathobiology [32-34].
Paving the path forward
Building the consensus necessary to shift regulatory guide-
lines, clinical trial design and clinical practice will require
large-scale cooperation among pharmaceutical and biotech
companies, academic leaders, advocacy groups, funders and
regulators. It is fortuitous that such cooperative efforts have
been steadily gaining traction in recent years. Regular
meetings involving all of the stakeholder groups have been
productive; the semiannual Alzheimer’s Association Research
Roundtable, the annual Leon Thal Symposium sponsored by
the Lou Ruvo Brain Institute, and the meetings of the Task
Force on Use of Biomarkers in Alzheimer’s Trials are leading
examples that have advanced the field. They demonstrate the
eagerness of many companies to share experience and ideas
in pursuit of solutions to problems in AD therapeutic research.
Perhaps the best example of a cooperative effort among
many to overcome the hurdles in drug development is ADNI.
Led by Michael Weiner at the University of California San
Francisco, ADNI is jointly funded by the National Institute on
Aging, the Alzheimer’s Association and other foundations,
and contributions from pharmaceutical companies. It is a
long-term effort to collect longitudinal cognitive, clinical, CSF
and neuroimaging data on cohorts of individuals with mild
AD, mild cognitive impairment and normal cognitive aging to
allow optimal use of biomarkers in trial design. ADNI brings
together leaders from academia, industry, government
agencies and advocacy groups on at least a biweekly basis to
jointly assess the study progress, and to discuss roadblocks
and paths forward. To maximize scientific advance, all ADNI
data are publicly posted in real-time; a huge number of
presentations and publications from ADNI as well as outside
investigators bears evidence of its success. ADNI has also
spawned or supported similar collaborative efforts in Europe,
Japan, Australia and China.
Data and ideas arising from ADNI and the various
collaborative meetings have provided the ideas and data
behind the discussion in this article. With continuation of
these efforts, the common goal of optimal trial design is
readily achievable. The challenges of determining populations
for study, cognitive and clinical outcome measures, validation
of biomarkers and analytic plans can be met within a few
years. Consensus will lead to practical regulatory pathways,
and the successful introduction of disease-modifying
interventions that will blunt the AD epidemic that is growing
with the aging world populations.
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